Moreover, we found that the combination of gemcitabine and nab-paclitaxel, a standard-of-care regimen for pancreatic cancer that has been combined with anti-CD40 in patients (20), also produced toxicity when administered at 2 days after anti-CD40 treatment. The gene discussed is CD40; the disease is familial pancreatic carcinoma.